Download 10552_2017_862_MOESM1_ESM

Supplemental Table 1. Selected Ovarian Cancer Association Consortium (OCAC) Papers1 Contributing to Knowledge of Epithelial Ovarian Cancer
Epidemiology
Author/Date
Type of
Analysis (E,
G, E/G)2
G
Exposure of Interest or
Confirmed Genetic Loci
Cancer Endpoint
9p22.2
EOC Susceptibility
Bolton, K.L.,et
al., 2010
G
19p13
EOC Susceptibility
Goode E.L., et
al., 2010
G
2q31 and 8q24
EOC Susceptibility
Pharoah, P.D.,
et al., 2013
G
EOC Susceptibility
Lawrenson, K.,
et al., 2015
G
8q21 (rs11782652);
10p12 (rs1243180) for all
EOC; 17q12 (rs757210)
for Serous EOC
Replicated: 3q25 and
17q21
CHEK2 gene locus
Kar, S.P.,et al.,
2015
G
17q21.32
(HOXB2,HOXB5, HOXB6,
HOXB7); 2q31 (HOXD1,
HOXD3)
Serous EOC
Susceptibility
Kelemen, L.E.,
et al., 2015
G
2q13 (rs752590); 2q31.1
(rs711830); 19q13.2
(rs688187)
Mucinous EOC
Susceptibility
Phelan, C.M.,
et al., (in
press)
G
Six loci for serous EOC:
Serous, Mucinous,
and Endometrioid
Susceptibility
Song, H., et
al., 2009
(3q28, 4q32.3, 8q21.11,
10q24.33, 18q11.2 and
EOC Susceptibility
Full Citation
Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E,
Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T,
Goode EL, et al. A genome-wide association study identifies a new
ovarian cancer susceptibility locus on 9p22.2. Nature genetics 2009;41:
996-1000
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T,
Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, et al.
Common variants at 19p13 are associated with susceptibility to ovarian
cancer. Nature genetics 2010;42: 880-4.
Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M,
Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK,
Birrer MJ, Berchuck A, et al. A genome-wide association study identifies
susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature genetics
2010;42: 874-9.
Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K,
Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, et al.
GWAS meta-analysis and replication identifies three new susceptibility
loci for ovarian cancer. Nature genetics 2013;45: 362-70, 70e1-2.
Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ,
Li Q, Marks JR, Berchuck A, Lee JM, Aben KK, Anton-Culver H, et al.
Common variants at the CHEK2 gene locus and risk of epithelial ovarian
cancer. Carcinogenesis 2015;36: 1341-53.
Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H,
Antonenkova N, Chenevix-Trench G, Baker H, Bandera EV, Bean YT,
Beckmann MW, et al. Network-Based Integration of GWAS and Gene
Expression Identifies a HOX-Centric Network Associated with Serous
Ovarian Cancer Risk. Cancer epidemiology, biomarkers & prevention : a
publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology 2015;24:
1574-84.
Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM,
Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, et al.
Genome-wide significant risk associations for mucinous ovarian
carcinoma. Nature genetics 2015;47: 888-97.
Phelan CM, Kuchenbaecker KB,*, Tyrer JP, Kar SP, Lawrenson K,
Winham SJ, Dennis J, Pirie A, Riggan M, Chornokur G, Earp MA, Lyra
PA,Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E , Lee A
, Barrowdale D, et al. Identification of twelve novel susceptibility loci for
Author/Date
Type of
Analysis (E,
G, E/G)2
Exposure of Interest or
Confirmed Genetic Loci
Cancer Endpoint
Full Citation
different histotypes of epithelial ovarian cancer. Nature Genetics 2017 (in
press).
22q12.1); two novel loci
for mucinous EOC:
(3q22.3, 9q31.1); one loci
for endometrioid EOC:
(5q12.3) three loci for
high grade serous: (2q13,
8q24.1 and 12q24.31)
Pearce, C.L. et
al., 2012
E
Endometriosis
EOC Risk
Terry, K.L., et
al., 2013
E
Genital Powder Use
EOC Risk
Olsen, C.M., et
al., 2013
E
Body Mass Index
EOC Risk
Trabert, B., et
al., 2014
E
Aspirin, NSAIDS,
Acetaminophen Use
EOC Risk
Cannioto, R.A.,
et al., 2016
E
Chronic Physical Inactivity
EOC Risk
Nagle, C.M., et
al., 2015
E
Body Mass Index
EOC Survival
Cannioto, R.A.,
E
Chronic Physical Inactivity
EOC Survival
Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM,
Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, ChangClaude J, Hein R, et al. Association between endometriosis and risk of
histological subtypes of ovarian cancer: a pooled analysis of case-control
studies. The Lancet Oncology 2012;13: 385-94.
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ,
Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen
K, Sieh W, et al. Genital powder use and risk of ovarian cancer: a pooled
analysis of 8,525 cases and 9,859 controls. Cancer prevention research
(Philadelphia, Pa) 2013;6: 811-21.
Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC,
Rossing MA, Terry KL, Wu AH, Risch HA, Yu H, Doherty JA, et al.
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian
Cancer Association Consortium. Endocrine-related cancer 2013;20: 25162.
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM,
Brinton LA, Webb PM, Nagle CM, Jordan SJ, Risch HA, Rossing MA, et
al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and
acetaminophen use and risk of invasive epithelial ovarian cancer: a
pooled analysis in the Ovarian Cancer Association Consortium. Journal of
the National Cancer Institute 2014;106: djt431.
Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE,
Eng KH, Brian Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R,
Gower E, Minlikeeva AN, et al. Chronic Recreational Physical Inactivity
and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer
Association Consortium. Cancer epidemiology, biomarkers & prevention :
a publication of the American Association for Cancer Research,
cosponsored by the American Society of Preventive Oncology 2016;25:
1114-24.
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A,
Fereday S, Hung J, Johnatty SE, Fasching PA, Beckmann MW,
Lambrechts D, et al. Obesity and survival among women with ovarian
cancer: results from the Ovarian Cancer Association Consortium. British
journal of cancer 2015;113: 817-26.
Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva
Author/Date
et al., 2016
Type of
Analysis (E,
G, E/G)2
Exposure of Interest or
Confirmed Genetic Loci
Cancer Endpoint
Full Citation
AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck
A, Chang-Claude J, et al. Recreational physical inactivity and mortality in
women with invasive epithelial ovarian cancer: evidence from the Ovarian
Cancer Association Consortium. British journal of cancer 2016;115: 95101
Clyde, M.A., et
E/G
Combination of
EOC Risk Prediction
Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA,
al., 2016
Epidemiological Risk
Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL, Wentzensen
N, Whittemore AS, et al. Risk Prediction for Epithelial Ovarian Cancer in
Factors and 17 Confirmed
11 United States-Based Case-Control Studies: Incorporation of
Genetic Loci
Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. American
journal of epidemiology 2016;184: 579-89.
1 Designated OCAC manuscripts were selected from over 100 publications, with the majority of publications focusing on genetic analyses; At the close of 2016,
approximately 60% of OCAC papers have been published in journals with impact factors greater than 5, while 20% have been published in journals with impact
factors greater than 10.
2E=environmental exposure; G=genetic exposure; E/G=environmental and genitic exposures
Supplemental Table 2. Selected Papers from OTTA, OC3 & the Oxford Collaborative Group
Consortium
The Ovarian
Tumor Tissue
Analysis
(OTTA)
consortium
The Ovarian
Cancer Cohort
Consortium
(OC3)
The
Collaborative
Group on
Author/Date
Exposure of
Interest
Biomarker based
ovarian cancer
subtyping
Cancer
Endpoint
IHC-based
histology
reclassification
Köbel M, et al.
2014
FOLR1 expression
EOC Survival
Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi
K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A,
Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall
C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S,
Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E,
Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A,
Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H,
Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE,
George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG,
Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a timedependent association between FOLR1 expression and survival from ovarian
carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis
consortium study.Br J Cancer. 2014 Dec 9;111(12):2297-307.
Sieh W, et al.
2013
Hormone-receptor
expression
EOC Survival
Wentzensen N,
Poole EM, et
al. 2016
Evaluation of 13
epidemiologic risk
factors by
histologic subtype
EOC Risk
The
Collaborative
Group on
Oral
contraceptives
EOC Risk
Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E,
Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB,
Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney
ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley
BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman
ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W,
Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein
JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E,
Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS,
Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL,
Huntsman DG, Ramus SJ. Hormone-receptor expression and ovarian cancer
survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013
Aug;14(9):853-62.
Wentzensen N*, Poole EM*, Trabert B, White E, Arslan A, Patel AV, Setiawan VW,
Visvanathan K, Weiderpass E, Adami H-O, Black A, Bernstein L, et al., Ovarian
Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer
Cohort Consortium. J Clin Oncol, 2016. 34(24): p. 2888-98.
*first co-authors
Collaborative Group on Epidemiological Studies of Ovarian, C., et al., Ovarian cancer
and oral contraceptives: collaborative reanalysis of data from 45 epidemiological
studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet,
Köbel M, et al.
2013
Manuscript Citation
Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley
BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB,
Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther
SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL;
Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma
typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86.
Consortium
Author/Date
Epidemiologic
al Studies of
Ovarian
Cancer
(Oxford
Collaborative
Group)
Epidemiological
Studies of
Ovarian Cancer
The
Collaborative
Group on
Epidemiological
Studies of
Ovarian Cancer
The
Collaborative
Group on
Epidemiological
Studies of
Ovarian Cancer
The
Collaborative
Group on
Epidemiological
Studies of
Ovarian Cancer
Exposure of
Interest
Cancer
Endpoint
Manuscript Citation
2008. 371(9609): p. 303-14.
Menopausal
Hormone Therapy
EOC Risk
Beral, V., et al., Menopausal hormone use and ovarian cancer risk: individual
participant meta-analysis of 52 epidemiological studies. Lancet, 2015. 385(9980):
p. 1835-42.
Body Size
EOC Risk
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Ovarian cancer
and body size: individual participant meta-analysis including 25,157 women with
ovarian cancer from 47 epidemiological studies. PLoS Med, 2012. 9(4): p.
e1001200.
Smoking
EOC Risk
Collaborative Group on Epidemiological Studies of Ovarian, C., et al., Ovarian cancer
and smoking: individual participant meta-analysis including 28,114 women with
ovarian cancer from 51 epidemiological studies. Lancet Oncol, 2012. 13(9): p.
946-56.